|
Tabla 4: Proporciones agrupadas de resistencia a los antibióticos para Enterobacter spp. |
||||||
|
Resistencia % |
General N = 419 n (%) |
2020 N = 64 n (%) |
2021 N = 74 n (%) |
2022 N = 133 n (%) |
2023 N = 87 n (%) |
2024 N = 61 n (%) |
|
Ampicilina- sulbactam |
316 (75.4) |
50 (78.1) |
57 (77.0) |
102 (76.7) |
60 (69.0) |
47 (77.0) |
|
Ampicilina |
320 (76.4) |
50 (78.1) |
61 (82.4) |
102 (76.7) |
60 (69.0) |
47 (77.0) |
|
Amoxicilina- ácido clavulánico |
372 (88.8) |
62 (96.9) |
68 (91.9) |
114 (85.7) |
77 (88.5) |
51 (83.6) |
|
Ceftriaxona |
119 (28.4) |
20 (31.3) |
16 (21.6) |
31 (23.3) |
35 (40.2) |
17 (27.9) |
|
Cefotaxima |
97 (23.2) |
11 (17.2) |
14 (18.9) |
27 (20.3) |
30 (34.5) |
15 (24.6) |
|
Ciprofloxacino |
157 (37.5) |
33 (51.6) |
27 (36.5) |
47 (35.3) |
29 (33.3) |
21 (34.4) |
|
Gentamicina |
56 (13.4) |
9 (14.1) |
7 (9.5) |
14 (10.5) |
9 (10.3) |
17 (27.9) |
|
Levofloxacino |
407 (97.1) |
63 (98.4) |
72 (97.3) |
128 (96.2) |
85 (97.7) |
59 (96.7) |
|
Piperacilina- tazobactam |
194 (46.3) |
37 (57.8) |
39 (52.7) |
44 (33.1) |
33 (37.9) |
41 (67.2) |
|
Trimetoprima sulfametoxazol |
51 (12.2) |
7 (10.9) |
4 (5.4) |
19 (14.3) |
15 (17.2) |
6 (9.8) |
|
Amikacina |
145 (34.6) |
35 (54.7) |
26 (35.1) |
39 (29.3) |
25 (28.7) |
20 (32.8) |
|
Cefepima |
130 (31.0) |
33 (51.6) |
27 (36.5) |
41 (30.8) |
19 (21.8) |
10 (16.4) |
|
Cefuroxima |
163 (38.9) |
31 (48.4) |
30 (40.5) |
37 (27.8) |
45 (51.7) |
20 (32.8) |
|
Ertapenem |
25 (6.0) |
6 (9.4) |
2 (2.7) |
7 (5.3) |
7 (8.0) |
3 (4.9) |
|
Imipenem |
167 (39.9) |
33 (51.6) |
39 (52.7) |
41 (30.8) |
33 (37.9) |
21 (34.4) |
|
Meropenem |
9 (2.1) |
1 (1.6) |
2 (2.7) |
2 (1.5) |
3 (3.4) |
1 (1.6) |
|
Tetraciclina |
185 (44.2) |
28 (43.8) |
29 (39.2) |
62 (46.6) |
34 (39.1) |
32 (52.5) |
|
Tobramicina |
367 (87.6) |
63 (98.4) |
73 (98.6) |
125 (94.0) |
61 (70.1) |
45 (73.8) |
|
Ceftazidima |
85 (20.3) |
13 (20.3) |
12 (16.2) |
25 (18.8) |
21 (24.1) |
14 (23.0) |